CypMaster™ Human Liver Microsome CYP450 Phenotyping Kit (7-Inhibitor Panel)

Identifies specific CYP450 isoform contributions to drug metabolism through selective chemical inhibition in different sample types microsomes.

CypMaster™

ADME

Metabolism

The CypMaster™ Human Liver Microsome CYP450 Phenotyping Kit (7-Inhibitor Panel) provides a specialized in vitro system for reaction phenotyping. By utilizing highly selective inhibitors, this kit quantifies the fractional contribution (fm) of major isoforms to total hepatic biotransformation, ensuring accurate prediction of clinical drug-drug interaction risks within female-specific metabolic profiles.

Isoform Selectivity: Utilizes seven rigorously validated, high-selectivity chemical inhibitors to ensure precise identification of specific enzymatic biotransformation and clearance pathways.
Optimized Biological Matrix: Employs characterized female human liver microsomes to address gender-specific metabolic profiles essential for comprehensive regulatory safety filings.
Ready-to-Use Workflow: Integrated kit includes standardized buffers and an NADPH regeneration system, facilitating rapid, high-throughput setup for LC-MS/MS analysis.
Reproducible Performance: Stringent quality control of microsomal enzymatic activity ensures consistent results across different batches for longitudinal drug development programs.

Predicts clinical drug-drug interaction potential by identifying specific enzymes responsible for a candidate molecule's hepatic metabolic clearance.

Lead optimization, preclinical ADME characterization, and regulatory-compliant in vitro metabolism and drug interaction studies.

Reaction phenotyping, determining fm values for major CYPs, assessing metabolic stability, ADME profiling studies and predicting inhibitory or inductive effects in specific populations.

Internal performance validation using reference standards under defined assay conditions.

Seven human liver CYP450 isoforms

Quantitative

Pharmacokinetics (ADME), drug-drug interactions (DDI), oncology therapeutics, clinical pharmacology, etc.

100 tests

Quantitative measurement of enzyme-specific inhibition and fractional contribution to total substrate biotransformation.

Human

Quantitative

Upon receipt, store the kit in accordance with the storage conditions specified in the product manual.

Avoid repeated freeze-thaw cycles. During use, minimize the time components are exposed to room temperature and return them promptly to -20°C; storage after handling. Do not store at elevated temperatures for extended periods.

12 months under recommended storage conditions to ensure optimal performance.

For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.

For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.

Shipped on ice under temperature-controlled conditions.

Cytochrome P450 enzymes are the primary drivers of Phase I oxidative metabolism. Identifying the specific isoforms involved in drug clearance is essential for managing patient safety and predicting inter-individual variability.

CYP450 enzymes catalyze the oxidation of lipophilic xenobiotics within the hepatic endoplasmic reticulum. This pathway requires electrons from NADPH, transferred via NADPH-cytochrome P450 reductase, to facilitate systemic drug detoxification.